R01HL162800
Project Grant
Overview
Grant Description
Mitochondrial Respiration as a Regulator of Lymphatic Cell Fate and Therapeutic Lymphangiogenesis - Summary
Endothelial cell (EC) metabolism has emerged as an essential driver and regulator of blood and lymphatic vessel development, as well as an alternative approach in anti-angiogenic therapy. It has been shown that metabolism is not only vital to EC function but also to controlling different steps of the (lymph)-angiogenic process.
Lymphatic vessels show remarkable plasticity and heterogeneity, reflecting their functional specialization to control the tissue microenvironment. Our recent findings revealed that by sensing the lymphatic endothelial cell (LEC) differentiation status and microenvironmental metabolic conditions, mitochondrial complex III regulates LEC fate specification and maintenance during embryonic development.
Similar to what was shown for blood endothelial cells, most likely in different pathological conditions, mitochondrial respiration is also required for the growth and expansion (lymphangiogenesis) of lymphatics. We argue that mitochondrial respiration sensing and regulation of the metabolic status of LECs is a critical step during developmental and disease-promoted lymphangiogenesis, and we will evaluate this proposal in mouse models of cardiac injury and induced acute and chronic pancreatitis.
Endothelial cell (EC) metabolism has emerged as an essential driver and regulator of blood and lymphatic vessel development, as well as an alternative approach in anti-angiogenic therapy. It has been shown that metabolism is not only vital to EC function but also to controlling different steps of the (lymph)-angiogenic process.
Lymphatic vessels show remarkable plasticity and heterogeneity, reflecting their functional specialization to control the tissue microenvironment. Our recent findings revealed that by sensing the lymphatic endothelial cell (LEC) differentiation status and microenvironmental metabolic conditions, mitochondrial complex III regulates LEC fate specification and maintenance during embryonic development.
Similar to what was shown for blood endothelial cells, most likely in different pathological conditions, mitochondrial respiration is also required for the growth and expansion (lymphangiogenesis) of lymphatics. We argue that mitochondrial respiration sensing and regulation of the metabolic status of LECs is a critical step during developmental and disease-promoted lymphangiogenesis, and we will evaluate this proposal in mouse models of cardiac injury and induced acute and chronic pancreatitis.
Awardee
Funding Goals
TO FOSTER HEART AND VASCULAR RESEARCH IN THE BASIC, TRANSLATIONAL, CLINICAL AND POPULATION SCIENCES, AND TO FOSTER TRAINING TO BUILD TALENTED YOUNG INVESTIGATORS IN THESE AREAS, FUNDED THROUGH COMPETITIVE RESEARCH TRAINING GRANTS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Chicago,
Illinois
606113015
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 292% from $771,042 to $3,026,108.
Northwestern University was awarded
Metabolic Regulation of Lymphatic Cell Fate Therapeutic Lymphangiogenesis
Project Grant R01HL162800
worth $3,026,108
from National Heart Lung and Blood Institute in July 2022 with work to be completed primarily in Chicago Illinois United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.837 Cardiovascular Diseases Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 7/25/25
Period of Performance
7/1/22
Start Date
6/30/26
End Date
Funding Split
$3.0M
Federal Obligation
$0.0
Non-Federal Obligation
$3.0M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01HL162800
Additional Detail
Award ID FAIN
R01HL162800
SAI Number
R01HL162800-3197468836
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
KG76WYENL5K1
Awardee CAGE
01725
Performance District
IL-05
Senators
Richard Durbin
Tammy Duckworth
Tammy Duckworth
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,542,084 | 100% |
Modified: 7/25/25